Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PET/CT provides MCL staging information

Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.

Key clinical point: PET/CT provided accurate staging information on mantle cell lymphoma without the use of bone marrow biopsy.

Major finding: If greater than 38% of the voxels demonstrated an standard uptake value of less than 0.95, there was a sensitivity of 100% and a specificity of 80%.

Study details: A retrospective cohort study of 23 patients with mantle cell leukemia and 5 controls.

Disclosures: There was no external funding for the study and the researchers reported having no financial disclosures.

Read the article.

Citation:

Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.

This Week's Must Reads

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894

For lymphoma patients, insurance is a matter of life or death , Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035

Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA

Promise of broad genomic testing of NSCLC disappoints in community oncology , Presley CJ et al. JAMA. 2018 Aug 7. doi: 10.1001/jama.2018.9824

Must Reads in Lymphoma & Plasma Cell Disorders

Private Insurance Linked to Better Outcomes in Follicular Lymphoma, Goldstein JS et al. Blood. 2018 Jul 24. doi: 10.1182/blood-2018-03-839035.

PET/CT provides MCL staging information, Morgan R et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 4. doi: 10.1016/j.clml.2018.06.024.

Durable responses seen from lisocabtagene in relapsed/refractory DLBCL, Abramson JS et al. ASCO 2018. Abstract 7505

Revised International Pediatric Non-Hodgkin Lymphoma Staging System, Expert panel publishes evidence-based system

Link Between Vitamin D and Lymphoma Survival, Analysis of patients in SWOG and LYSA trials